CSCJC3456

CSCJC3456 is an orally bioavailable small molecule inhibitor specifically targeting the **KRAS G12D** mutation. Developed by Changshan ConjuChem Biopharmaceutical, the agent is designed to treat advanced malignant solid tumors that harbor this specific oncogenic driver, which is particularly prevalent in pancreatic, colorectal, and non-small cell lung cancers. By binding to the KRAS G12D mutant protein, CSCJC3456 inhibits the constitutive activation of the KRAS signaling pathway, thereby suppressing tumor cell proliferation and survival. It is currently undergoing Phase Ia/Ib clinical evaluation to determine its safety, pharmacokinetics, and preliminary anti-tumor activity in patients with refractory solid tumors.